Lipicure CV 40mg/75mg Capsule is a combination pharmaceutical formulation containing Atorvastatin 40mg and Clopidogrel 75mg, indicated for the management of cardiovascular diseases. Atorvastatin, a potent HMG-CoA reductase inhibitor, effectively reduces low-density lipoprotein cholesterol (LDL-C) and total cholesterol levels, thereby decreasing the risk of atherosclerotic plaque formation and subsequent cardiovascular events. Clopidogrel, an antiplatelet agent, inhibits platelet aggregation by irreversibly blocking the P2Y12 component of ADP receptors on platelet surfaces, reducing the risk of thrombotic events such as myocardial infarction and stroke. Lipicure CV is primarily prescribed for patients with established coronary artery disease, recent myocardial infarction, or those at high risk of thrombotic complications. The combination therapy offers synergistic benefits by addressing both lipid abnormalities and platelet aggregation, thus improving cardiovascular outcomes. Patients should adhere to prescribed dosages and undergo regular monitoring of lipid profiles, liver function tests, and hematological parameters to detect potential adverse effects. Common side effects may include gastrointestinal disturbances, myalgia, bleeding tendencies, and elevated liver enzymes. Caution is advised in patients with hepatic impairment, bleeding disorders, or those concurrently using other anticoagulants. Lipicure CV should be used under strict medical supervision to optimize therapeutic efficacy and minimize risks.